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Aims We aimed to study the diagnostic inﬂuence of adding a routine cardiovascular ultrasound screening of the cardiac
anatomy and function, the pericardium, the pleura and the abdominal great vessels by the new pocket-size ultrasound
device (pUS) with grey scale and colour Doppler imaging.
Methods
and results
In 119 randomly selected patients admitted to a cardiac unit at a non-university hospital, routinely adding a cardio-
vascular ultrasonography of only 4.4 min with a pocket-size device corrected the primary diagnosis in 16% of patients.
In addition, 29% had the primary diagnosis veriﬁed and in 10% an additional important diagnosis was made. Higher age
predicted any diagnostic inﬂuence of pUS screening with an increase of 61% (P ¼ 0.003) per 10 years of higher age.
Overall, the pUS screening had a sensitivity and speciﬁcity with respect to detecting at least moderate pathology of 97
and 93%. Positive and negative predictive values were 93 and 87%, respectively. In the sub-group of subjects with a
change in the primary diagnosis following pUS there was no false-negative or false-positive ﬁndings.
Conclusion Screening by pUS assessed vascular and cardiac anatomy and function accurately and enabled correction of the diag-
nosis in 16% of patients admitted to a cardiac unit. In 55% of the participants, the cardiovascular ultrasound screening
had important diagnostic inﬂuence. We suggest that it would be appropriate to implement strategies and systems for
routinely adding an ultrasound cardiovascular examination to patients in cardiac units.
-----------------------------------------------------------------------------------------------------------------------------------------------------------
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Introduction
Diagnosis and treatment are the key elements in every inpatient’s
stay. Unfortunately, a correct diagnosis is not always made in time
with a possible non-favourable outcome, time delay and patient’s
suffering as the result.
1 Former studies have shown that adding an
echocardiographic or cardiovascular ultrasound examination to
the usual care diagnostics improve the accuracy of the diagno-
sis.
2–5 The last decade’s miniaturization of ultrasound devices
capable of offering high-quality recordings has made possible a
logistic basis for applying ultrasound examinations in a more
routine way. The pocket-size ultrasound devices (pUS) of the
last years have the potential to dramatically rearrange physical
examinations and diagnosis.
6,7 The pUS has been shown to be
both accurate and feasible as a tool for cardiac imaging when
used by experienced operators.
8–10 However, it is not known
how the pUS could be used as a tool in a cardiac unit inﬂuence
diagnosis. In addition, it is uncertain how reliable the pUS exam-
inations are when they are performed at the bedside under non-
optimal conditions. We therefore aimed to study the diagnostic
inﬂuence of routinely adding a bedside pUS cardiovascular
screening with examination of the heart, the pericardium, the
pleura and the abdominal great vessels. Furthermore, we
wanted to study the reliability of the bedside pUS examination,
and at last, study predictors of diagnostic inﬂuence of the pUS
cardiovascular screening.
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Study population
Patients admitted to the unit of cardiovascular medicine at the non-
university Levanger Hospital in Norway between March and Septem-
ber 2010 were available for inclusion in this cardiovascular ultrasound
study. As the second-call duty at this hospital is served by three cardi-
ologists experienced in echocardiography and abdominal ultrasound
and 10 other specialists in internal medicine, patients were only avail-
able for inclusion if one of the three cardiologists were on call the day
the patients were admitted to the department. Prior to inclusion,
patients were examined in the emergency department by a junior
and senior resident. From medical history, clinical examination, labora-
tory tests and goal-directed imaging procedures other than echocar-
diography the primary diagnosis was made. All of these newly
admitted patients who were available at the unit at the cardiologists
evening round were included if they consented to participate. In
total 119 patients were included in the study and screened by cardio-
vascular ultrasound.
The study was approved by the Regional Committee for Medical
Research Ethics and conducted according to the second Helsinki
Declaration. Written informed consent was obtained from all partici-
pants. Patients not able to consent were not included.
Diagnostic usefulness of screening with
pocket-size ultrasound
Prior to the pUS examination, the primary diagnosis was recorded in
the patient’s journal ﬁles. Secondly, the results of the bedside pUS
screening and the cardiologist own opinion of the diagnostic usefulness
of the pUS screening were reported according to European Association
of Echocardiography (EAE) recommendations.
11 Thirdly, the Study
Committee, consisting of two internal and one external (Trondheim
University Hospital) cardiologists experienced in echocardiography
and abdominal ultrasonography, graded the diagnostic usefulness of
the bedside pUS screening. From the patients’ journal ﬁles, the Commit-
tee individually graded the diagnostic usefulness as: (i) change in the
primary diagnosis, (ii) veriﬁcation of the primary diagnosis, (iii) added
diagnosis important for further treatment or follow-up of the patient
or (iv) not useful, depending on the descriptions of diagnosis, ﬁndings
and therapeutic inﬂuence. In case of doubt, the clear majority in the
Committee decided the grading of the diagnostic usefulness.
Cardiovascular screening
The cardiovascular screening was performed with a pUS, Vscan (GE
Vingmed Ultrasound, Horten, Norway). The device weighs 390 g,
including the phased-arrayed probe, which is sized 135 × 73 ×
28 mm. The device offers two-dimensional grey scale and colour
Doppler imaging, with a movable colour Doppler sector. The band-
width with a range of 1.7–3.8 MHz is automatically adjusted. An algor-
ithm enables automatic storage and looping of a cardiac cycle without
ECG signal.
12 The length of recordings of other structures is prede-
ﬁned and limited to 2 s. Patient identiﬁcation was performed by
voice recording and the automatically assessed examination number.
All images and recordings were saved on the device’s micro-SD
card, and later transferred to a computer by commercial software
(Gateway; GE Vingmed Ultrasound).
The cardiovascular screening by pUS was performed at the bedside
with patients in left-lateral decubitus and supine position. Assessment
of left ventricular (LV) global and regional function, right ventricular
(RV) size and function, valvular anatomy and function and the pericar-
dium were assessed from parasternal long- and short-axis and apical
four-chamber, two-chamber and long-axis views. Global LV and RV
functions were classiﬁed online by visual assessment as (i) normal/
near normal, (ii) moderate dysfunctional or (iii) severe dysfunctional,
while regional LV function was classiﬁed as (i) no regional dysfunction
or (ii) regional dysfunction present. Valvular anatomy and function
were classiﬁed as (i) normal/near normal anatomy and function, (ii)
moderate pathology/dysfunction or (iii) severe pathology/dysfunction
by visual assessment from grey scale and colour Doppler imaging.
The most severe valvular pathology was used in the analyses. Pericar-
dial effusion was classiﬁed as (i) not present or (ii) present. The size of
the left atrium was measured on grey-scale parasternal long-axis
measurement images by the device’s caliper mode. An attempt was
made in order to do the measurement at end systole. From the sub-
xiphoid position, the abdominal aorta and inferior vena cava were
assessed by grey-scale imaging. The abdominal aorta was assessed dis-
tally to the bifurcation and classiﬁed as (i) no abdominal aortic aneur-
ysm present and (ii) abdominal aortic aneurysm present, depending on
whether the diameter exceeded 35 mm or not. Maximal dimension
was measured in case of doubt by visual assessment. The inferior
vena cava diameter was measured end expiratory within 2 cm from
the right atrium oriﬁce and respiratory variation was assessed to esti-
mate the right atrium ﬁlling pressure.
13 All measurements of size were
done on the pUS. With patients in the supine position the pleura was
assessed by grey-scale imaging from left and right lateral views, and the
amount of pleural effusion was classiﬁed as (i) no pleural effusion, (ii)
insigniﬁcant or moderate pleural effusion or (iii) signiﬁcant pleural effu-
sion.
14 All recordings were saved on the pUS and the time used for the
screening was calculated as the time from start to end of the
examination.
Validation of pUS screening
A high-end echocardiographic examination was performed by a Vivid 7
(GE Vingmed Ultrasound) scanner. One of the four experienced car-
diologists other than the one who performed the pUS screening per-
formed the examination. They were blinded to the result of the pUS
examination. The same cardiovascular structures as described above
were measured and classiﬁed according to the guidelines of the
EAE.
15–19 Ejection fraction was measured by Simpson’s rule from
apical four-chamber and two-chamber views, dimensions were
measured by motion mode from parasternal recordings.
18 Valvular
pathology was graded according to the recommendations from the
EAE.
15–17 In addition, imaging techniques as computer tomography,
magnetic resonance imaging or ultrasound were used by usual care
at the Department of Radiology. For the analyses in the patients
who underwent both echocardiographic and radiologic examinations,
the radiologists grading of pleural effusion and size of the abdominal
aorta was preferred compared with the echocardiography. At last all
examinations were graded as described for pUS.
Statistics
As the different echocardiographic and anthropometric measures
partly deviated from normal distribution, the basic characteristics are
presented as mean + standard deviation (SD) and range. Comparison
of continuous variables between groups was done by the
non-parametric Mann–Whitney U test of independent samples, and
proportions between groups were analysed by the x
2 test or
Fisher’s exact test. The Spearmans rho (r) is used for comparison of
the grading of pathology between the pUS and the high-end echocar-
diographic or radiologic examinations. Data are presented as r [95%
conﬁdence interval (CI)] where the 95% CI is analysed by determining
the bootstrap distribution randomly re-sampling the study population
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pUS and the high-end examinations Pearson’s rho (r) was used,
respectively. In order to assess predictors of inﬂuence of the pUS
screening, logistic regression analyses were used. Diagnostic inﬂuence,
graded as diagnostic usefulness or no diagnostic usefulness, was used as
the dependent variable, and the age and known increased risk of car-
diovascular disease were used as explanation variables. As there was a
linear relationship between the diagnostic usefulness and increasing
age, age was entered into the analyses as a continuous variable.
Increased risk was classiﬁed as present if the patients had any known
cardiovascular disease, hypertension or diabetes. Sample size of
around 100 participants was estimated by expecting a change in the
main diagnosis of at least 8–10% points, in addition to a more pro-
nounced proportion in which the diagnose was veriﬁed or another
important diagnose was added. However, from these estimates we
expected only around 50–70% power to detect signiﬁcant predictors
of diagnostic usefulness of pUS screening with respect to change in the
main diagnosis, and some underpowered analyses with respect to
detecting predictors of any diagnostic usefulness as well (Sample-
Power, SPSS, Inc., Chicago, IL, USA). All the statistical analyses were
performed using SPSS for Windows (version 18.0, SPSS, Inc.).
Results
Study population
Table 1 shows basic characteristics of the 119 study participants
(45 women and 74 men). Mean+SD (range) age was 67+15
(25–85) years among women and 66+14 (20–89) years among
men, with no signiﬁcant difference (P ¼ 0.31). The distribution of
age departed from the normal distribution and was positively
skewed (Figure 1), P , 0.001. Each of the pUS measurements
was obtained in at least 78% of the participants, and complete visu-
alization of the abdominal aorta and the inferior vena cava diam-
eter had lowest feasibility. Except for these latter measurements,
all structures were assessed to satisfaction in at least 98% of the
participants. A total of 65% had previous known atrial ﬁbrillation,
hypertension, diabetes or any kind of known cardiovascular
disease and these participants were classiﬁed as at increased cardi-
ovascular risk. The time used for the bedside pUS screening was
4.4+1.7 (2.0–13) min.
Diagnostic usefulness of screening with
pocket-size ultrasound
The diagnostic usefulness of bedside cardiovascular ultrasound
screening with the pocket-size Vscan is shown in Table 2 and
Figures 2 and 3. In 19 (16%) participants the primary diagnosis
was changed following pUS. In a total of 65 (55%) patients there
was diagnostic usefulness, classiﬁed as either change in primary
diagnosis, veriﬁcation of primary diagnosis or adding a diagnosis
important for treatment or follow-up of the patient. In Table 3
basic characteristics, the primary diagnosis, the ﬁndings and the
correct diagnosis after pUS screening are listed for the 19 patients,
with a change in the primary diagnosis following the pUS screening.
................................................................................
Table 1 Basic characteristics of 119 study participants
Mean+ + + + +SD (range)
Age (years) 66.5+14.2 (20–89)
Women [n (%)] 45 (38)
Height (cm) 172+9 (146–189)
Weight (kg) 80+15 (45–122)
Body mass index (kg/m
2) 27.4+4.9 (17–44)
Systolic blood pressure (mmHg) 146+31 (58–250)
Diastolic blood pressure (mmHg) 80+20 (32–161)
Heart rate (bpm) 81+24 (29–150)
Atrial ﬁbrillation [n (%)] 19 (16)
Known hypertension [n (%)] 44 (37)
Known diabetes [n (%)] 19 (16)
Known myocardial infarction [n (%)] 34 (29)
Known angina [n (%)] 26 (22)
Known heart failure [n (%)] 10 (8)
Known peripheral vessel disease [n (%)] 9 (8)
Known stroke [n (%)] 8 (7)
Increased cardiovascular risk [n (%)] 77 (65)
Known cancer [n (%)] 4 (3)
Increased cardiovascular risk; previous known atrial ﬁbrillation, hypertension,
diabetes or any kind of known cardiovascular disease.
Figure 1 Age distribution of the 119 participants. Distribution
deviated signiﬁcantly from normal distribution (P , 0.001).
................................................................................
Table 2 Diagnostic inﬂuence of bedside
cardiovascular screening by pocket-size ultrasound in
119 study participants
Diagnostic inﬂuence Number (%)
Change in primary diagnosis 19 (16%)
Veriﬁcation of primary diagnosis 34 (29)
Additional diagnosis made 12 (10)
No diagnostic usefulness 54 (45)
Cardiovascular screening by pUS 739Figure 4 show the electrocardiogram and an echocardiographic
image of one of the patients who had the diagnosis changed.
Age and known increased risk of cardiovascular disease of the
study participants differed signiﬁcantly between those with any
diagnostic inﬂuence of the pUS screening and those without.
Mean age was almost 10 years higher in those where pUS screen-
ing inﬂuenced the diagnosis (P , 0.001) with mean+SD (range)
70.9+11.7 (38–89) compared to 61.2+15.2 (20–85). The pro-
portion of participants with increased cardiovascular risk, assessed
as previous known atrial ﬁbrillation, hypertension, diabetes, angina,
myocardial infarction, heart failure, peripheral vessel disease or
stroke, was 75% in those with any diagnostic usefulness of pUS
screening compared to 52% in the other group (P ¼ 0.007).
Figure 2 shows the probability and 95% CI of diagnostic usefulness
of pUS screening according to pre stratiﬁed age groups (,40, 40–
59.9, 60–79.9 and .80 years). Figure 3 illustrates diagnostic inﬂu-
ence of the pUS screening according to the two age groups of
participants between 40 and 80 years. In logistic regression ana-
lyses 10 years higher age was found to increase the probability
of any diagnostic inﬂuence of pUS screening with 61% (P ¼
0.003) adjusted for increased cardiovascular risk as present or
absent (Table 4), but the corresponding 33% (P ¼ 0.2) increased
probability of change in primary diagnosis was not signiﬁcant. Cor-
respondingly, increased cardiovascular risk, assessed as present or
absent, did not show signiﬁcant increased probability of changed
primary diagnosis or any diagnostic use when adjusted for age (P
≥ 0.14). However, as shown in Table 4 there was a clear trend
towards increased probability of diagnostic usefulness of cardiovas-
cular bedside screening with pUS in those with higher cardiovascu-
lar risk. The other basic characteristics did not predict diagnostic
usefulness of the cardiovascular screening with pUS.
Validation of pUS screening
Validation of pUS screening was tested in a sample of 90 (76%) of
the population. The correlation coefﬁcient was1.0 for the grading
of pericardial effusion and detection of abdominal aortic aneurysm,
0.94 (CI: 0.88–0.99) and 0.92 (CI: 0.83–0.99) for the grading of
global and regional LV functions, respectively, 0.84 (CI: 0.60–1.0)
for the grading of RV size and function, 0.89 (CI: 0.81–0.95) for
the grading of valvular function, 0.67 (CI: 0.54–0.79) for the assess-
ment of end-expiratory size of the inferior vena cava and 0.66 (CI:
0.51–0.78) for left atrium. All correlations were very highly signiﬁ-
cant (all P , 0.001). The inferior vena cava and the complete
abdominal aorta were available for comparison in 81 (90%) and
59 (66%), respectively. All other structures were feasible in at
least 97% of the participants.
In analyses of the 90 subjects that had been re-examined with at
least one of the high-end reference methods, the sensitivity and
speciﬁcity of the pUS examination with respect to detecting mod-
erate or severe pathology of LV global and regional functions, RV
function, valvular function and dilatation of the left atrium, detec-
tion of pericardial or pleural effusion as well as abdominal aortic
aneurysms was 97 and 93%. The corresponding positive and nega-
tive predictive values were 93 and 87%, respectively. In the 19 sub-
jects with change in the primary diagnosis following pUS there was
no misclassiﬁcation at all.
Discussion
In 119 randomly selected patients admitted to a cardiac unit at a
non-university hospital routinely adding a cardiovascular ultrasono-
graphy of only 4.4 min with a pocket-size device corrected the
primary diagnosis in 16% of patients. In addition, 29% had the
primary diagnosis veriﬁed and in 10% an additional important diag-
nosis was made. Thus, in only 45% of the participants the cardio-
vascular ultrasound screening had no diagnostic inﬂuence.
Figure 3 Diagnostic inﬂuence of cardiovascular ultrasound
screening of participants 40–79.9 years. Diagrams show diagnos-
tic inﬂuence of cardiovascular screening by pocket-size ultra-
sound according to the pre-stratiﬁed age groups 40–59.9 (left)
and 60–79.9 years (right).
Figure 2 Diagnostic inﬂuence of cardiovascular ultrasound
screening according to age. The probability of diagnostic inﬂuence
of cardiovascular screening by pocket-size ultrasound according
to the pre-stratiﬁed age groups. Error bars refer to 95% conﬁ-
dence interval.
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Median age was 69 years, and as shown in Figure 1 the distribution
of age was positively skewed. The basic characteristics are in line
with those published in former studies
3,5,20 and thus, it might
reﬂect the everyday clinical setting at cardiac departments.
Diagnostic usefulness of pUS screening
The diagnostic inﬂuence of routinely adding a pocket-size cardio-
vascular ultrasound examination performed by experts are
remarkable, but still in line with previous publications on screening
of patient groups by larger mobile ultrasound devices.
3–5 The cost-
beneﬁt of a screening programme depends on the accuracy of the
method used and the prevalence of pathology in the popu-
lation.
21,22 This study, as well as others, shows the high prevalence
of underlying disease among inpatients with suspected cardiac or
internal medical diseases.
3–5 Furthermore, it underlines how difﬁ-
cult it is to make a correct diagnosis based on medical history, clini-
cal examination, laboratory tests and routine imaging alone.
1–5
Even though many of the incorrect diagnosis would have been cor-
rected during the patient’s stay, usual care practice would have lead
to a signiﬁcant time delay as well as a probable misdiagnosing. The
accuracy of pUS screening presented is in line with recent publi-
cations performed under more optimized conditions compared
with examinations performed bedside.
8–10 We therefore suggest
that screening with cardiovascular ultrasound in addition to usual
care examinations should be recommended in patients admitted
to a cardiac unit to optimize diagnostic accuracy and inpatient
workﬂow. The use of pUS devices is quick, accurate and cheap,
and thus, it has the potential to dramatically change the inpatient
and outpatient workﬂow.
6,7,10,23–25
Not surprisingly patient’s age and level of cardiovascular risk
predicted the diagnostic usefulness of the cardiovascular pUS
screening. Former studies in comparable populations are scarce,
2
but these ﬁndings are in line with the conceptual fundamentals
of screening programmes, as the risk of diseases inﬂuences the
outcome.
21,26 Increased risk of cardiovascular disease assessed as
known atrial ﬁbrillation, known hypertension, known diabetes or
any kind of known cardiovascular disease did not signiﬁcantly
predict diagnostic inﬂuence of pUS screening when adjusted for
age. However, there was a clear trend. This may be explained by
the fact that this study was not optimally powered to detect differ-
ent predictors of diagnostic inﬂuence of pUS screening. As shown
...............................................................................................................................................................................
Table 3 Characteristics and ﬁndings of the 19 participants with a change in primary diagnosis after cardiovascular
screening with pocket-size ultrasound
Characteristics Primary
diagnosis
Main ﬁndings at bedside screening with pocket-size
cardiovascular ultrasound
Changed diagnosis
M, 75 years, HT, MI, op. CABG Dyspnea AAA 56 mm, PE, PlE PE, AAA
W, 82 years, HT, AP, op. AVR Dyspnea PlE PlE, severe amount
M, 78 years, asthma Chest pain Aortic valve stenosis/insufﬁciency Aortic stenosis
W, 83 years, HT, COPD Dyspnea LAI? PlE, moderate valvular insufﬁciencies, LV dysfunction Heart failure
M, 75years, AFIB, AP, PerVes,
COPD
Heart failure Normal LV and RV function COPD
W, 60 years, HT Chest pain LVH Hypertensive heart
disease
W, 64 years, HT Chest pain Dissection of thoracic and abdominal aorta Aortic dissection
W, 59 years, HT, DM NSTEMI Dilated and dysfunctional LV, multi-valvular pathology Heart failure
M, 70 years, AFIB AFIB Anterior wall dysfunction NSTEMI
W, 58 years, HT Chest pain Anteroseptal wall dysfunction NSTEMI
W, 80 years, HT, DM, PerVes Pneumonia Dilated and dysfunctional LV Heart failure
W, 67 years, AFIB, HT, DM AFIB Severe LA dilatation, dilated IVC, PlE Heart failure
M, 62 years, MI, AP Dyspnea Global and regional LV dysfunction, severe MR Heart failure (MR)
W, 81 years, HT, PerVes,
stroke
a
Chest pain LVH, moderate MI, severe dilated IVC Hypervolemia (HF)
W, 81 years, HT, op. Pneumonia RV dilatation and dysfunction, dilated IVC Ac. cor pulmonale
(PuE?)
M, 53 years, asthma NSTEMI? Severe LV dilatation and dysfunction DCM
W, 56 years, asthma PuE Inferior wall dysfunction NSTEMI
M, 87 years, MI, AP, HF Heart failure Severe AS, PlE, near normal LV function Severe AS
W, 81 years, MI Dizziness AAA 100 mm AAA
AAA, abdominal aortic aneurysm; AFIB, atrial ﬁbrillation; AP, angina; AS, aortic stenosis; AVR, aortic valve replacement; DCM, dilated cardiomyopathy; DM, diabetes mellitus; HF,
heart failure; HT, hypertension; IVC, inferior vena cava; LA, left atrium; LAI, lower airway infection; LV, left ventricular; LVH, left ventricular hypertrophy; MI, myocardial infarction,
MR, mitral regurgitation; NSTEMI, non-ST-elevation myocardial infarction; op., recent surgery; PE, pericardial effusion; PlE, pleural effusion; PuE, pulmonary embolism; COPD,
chronic obstructive pulmonic disease; PerVes, peripheral vessel disease.
aExcessive salt intake.
Cardiovascular screening by pUS 741by the results, the diagnostic inﬂuence of cardiovascular screening
with pUS seems to be apparent also at those at lowest age, and this
advocates screening examinations in similar populations without
further restriction with respect to age or risk. Similarly, former
publications have also recommended echocardiographic screening
in outpatient populations.
2,5,10,24 The beneﬁt of the screening pro-
cedure must be weighed against the possible harm. This refers par-
ticularly to possible false positive ﬁndings
22 as diagnostic
ultrasound have no acknowledged side effects.
27 The high-positive
and -negative predictive values in this study indicate that screening
programmes of similar populations may be cost beneﬁcial.
Validation
There was a very high accuracy of pUS screening compared with
high-end echocardiography or radiologic examinations for assess-
ment of aortic aneurysms, pericardial effusion, LV global and
regional size and function, RV size and function and valvular func-
tion. Assessment of size of the left atrium and end-expiratory
diameter of the vena cava was fair and in line with a recent publi-
cation.
8 With respect to these two structures, there are some
methodological aspects that might have inﬂuenced the results. As
the use of ECG cables is unpractical on pUS devices, the exact
timing in the cardiac cycle may be non-optimal on the pUS
device as it depends on visual assessment. However, the high accu-
racy with respect to detecting abdominal aortic aneurysms as well
as a almost perfect correlation for aortic dimension with r ¼ 0.99
(95% CI: 0.98–1.0) in those where aortic dimension was measured
with pUS indicates that the non-optimal accuracy of measuring size
of the left atrium and inferior vena cava is inﬂuenced by timing of
the measurement in the cardiac or respiratory cycle. In addition,
the time delay from the pUS screening to the high-end echocardio-
graphy was mean (SD) 16 h,
12 which may have inﬂuenced the
repeatability of the inferior vena cava measurements, due to phys-
iological reasons and treatment during the time period.
Conclusion
In this study we found that a quick cardiovascular ultrasound
screening by pUS assessed vascular and cardiac structures’ size
and function accurately and enabled correction of the diagnosis
in 16% of patients admitted to a cardiac unit. In addition, several
patients had their diagnosis veriﬁed or an additional diagnosis
important for treatment or follow-up made. We suggest that
implementing strategies and systems for routinely adding an ultra-
sound cardiovascular examination to patients in cardiologic units
are appropriate.
Limitations
The main limitation of this study is that the bedside cardiovascular
pUS screening was performed by consultant cardiologists experi-
enced in echocardiography as well as in abdominal ultrasonogra-
phy. How these ﬁndings correspond to non-expert use of pUS
have to be proved. Secondly, we studied patients admitted to a
non-university hospital without a catheterization laboratory.
Patients with ST elevation in pre-hospital electrocardiograms or
cardiogenic shock were directed to the regional university hospital
with catheterization laboratory facilities and were not included in
the acute phase of the disease. Thus, the study results may not
be generalized to such patient populations. However, the com-
plete cardiovascular pUS of 4 min makes it possible to do a fast
cardiovascular ultrasound screening also in such patients without
signiﬁcant time delay, and the evolving attention to the so-called
stress cardiomyopathies are examples of a potential beneﬁt of fol-
lowing the same strategies also in this patient group.
28 The possible
usefulness in such a population needs to be proved. The intention
was to validate all examinations, but due to internal logistics 29
(24%) of the pUS was not validated by high-end examinations.
Figure 4 Clinical case of a patient with change in diagnosis
after examination with pUS. A 64-year-old woman was admitted
with chest pain suspect of coronary ischaemia. Electrocardiogram
showed T-wave inversions in precordial leads (left ﬁgure).
Bedside screening with pocket-sized device revealed dissection
of the ascending aorta (right ﬁgure; modiﬁed ﬁve-chamber
view), aneurysm of the ascending aorta and aortic regurgitation.
Dissection membrane was also visible in the abdominal aorta.
She was transferred to the regional university hospital for
surgery. See Supplementary data online, video loops.
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Table 4 Predictors of any diagnostic inﬂuence of
bedside cardiovascular ultrasound screening
OR 95% CI OR P-value
Age per 10 years
a 1.72 (1.27–2.32) ,0.001
Any increased cardiovascular risk
b 2.84 (1.31–6.18) 0.008
Age per 10 years
c 1.61 (1.17–2.21) 0.003
Any increased cardiovascular risk
d 1.89 (0.81–4.39) 0.14
Any usefulness is changed primary diagnosis, veriﬁed diagnosis or additional
diagnosis.
CI, conﬁdence interval; OR, odds ratio.
aNot adjusted for cardiovascular risk,
bNot adjusted for age,
cAdjusted for cardiovascular risk
dAdjusted for age.
K. Skjetne et al. 742Out of these patients the numbers with changed diagnosis, veriﬁed
diagnosis, added important diagnosis and no diagnostic usefulness
of pUS was 1, 2, 2 and 24, respectively. For those of diagnostic
importance, these ﬁndings were veriﬁed on the same recording,
but these examinations were excluded from the validation ana-
lyses. No data are available from those who did not consent to
participate. There was only around 50–70% power to detect sig-
niﬁcant predictors of diagnostic usefulness of pUS screening with
respect to change in main diagnosis, and some underpowered ana-
lyses with respect to detecting predictors of any diagnostic useful-
ness as well.
Supplementary data
Supplementary data are available at European Journal of
Echocardiography online.
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